PRNewsWire - Health

Biodefense Market worth $1.81 billion by 2030 - Exclusive Report by MarketsandMarkets™
May in Review: 14 Top Health Press Releases
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
/C O R R E C T I O N from Source -- Ario Khoshbin/